Effectiveness of micronized progesterone for the prevention of miscarriage

• Khalid Haddad
• Olga K. Molchanova
• Kseniya I. Lee
• Sergey I. Kyrtikov
• Nozimabonu M. Zokirova
• Irina V. Bekbaeva
• Zhasmina Zh. Suleymanova
• Agamurad A. Orazmuradov

AbstractMiscarriage is one of the urgent problems in modern Healthcare. Over the past 3 years, the evidence base for spontaneous miscarriage gestagen therapy has been developed and supplemented very actively (from 2019, when the PRISM study results were published, until the end of 2021 and the Cochrane meta-analysis release). The accumulated scientific data are reflected in practical medical recommendations. The National Institute for Health and Care Excellence (NICE) at the end of 2021 released recommendations for spontaneous miscarriage management, where micronized vaginal progesterone is recommended as the only drug in case of threatened miscarriage.

Keywords:miscarriage; micronized progesterone

REFERENCES

1. Bender Atik R., Christiansen O.B., Elson J., Kolte A.M., Lewis S., Middeldorp S., et al. ESHRE guideline: recurrent pregnancy loss // Hum. Reprod. Open. 2018.

2. Brignardello-Petersen R., Bonner A., Alexander P.E., Siemieniuk R.A., Furukawa T.A., Rochwerg B., GRADE Working Group. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis // J. Clin. Epidemiol. 2018. Vol. 93. Р. 36-44.

3. Rovner P., Stickrath E., Alston M., Lund K. An early pregnancy unit in the United States: an effective method for evaluating firsttrimester pregnancy complications // J. Ultrasound Med. 2018. Vol. 37. Р. 1533-1538.

4. Ordiyants I.M., Barabasheva S.S. Non-developing pregnancy: view of the problem: Akusherstvo i ginekologiya: novosti, mneniya, obuchenie [Obstetrics and Gynecology: News, Opinions, Training]. 2018; 3: 92-6. (in Russian)

5. Rumyantseva Z.S., Lyumanova E.Yu., Volotskaya N.I., Anikin S.S. Predictors of non-developing pregnancy and role of periconceptional care in prevention of recurrent pregnancy loss. Medical newsletter of Vyatka. 2021. № 1 (69). (in Russian)

6. Devall A., et al. Progestogens for preventing miscarriage: a network metaanalysis // Cochrane Database of Systematic Reviews. 2021. N 4.

7. Volkov V.G., Chursina O.V. A role of comprehensive cervix assessment in the first trimester of pregnancy for predicting preterm. Akusherstvo, ginekologiya, reproduktsiya [Obstetrics, Gynecology, Reproduction]. 2020; 14 (2): 174-181. (in Russian)

8. Zagorodnikova K.A., Rustanovich Yu.G., Kostyuchek D.F., Murzina A.A. The frequency of rs776746 polymorphism in the CYP3A5 gene in women with nondeveloping pregnancy. Farmakogenetika i farmakogenomika [Pharmacogenetics and Pharmacogenomics]. 2018; 1: 27-30. DOI: 10.24411/2588-0527-2018-10005 (in Russian)

9. Brownlea S., Holdgate A., Thou S.T., Davis G.K. Impact of an early pregnancy problem service on patient care and emergency department presentations. Aust N Z J Obstet Gynaecol. 2017; 45: 108-111.

10. Ectopic pregnancy and miscarriage: diagnosis and initial management NICE guideline. 2019.

11. Coomarasamy A., et al. A randomized trial of progesterone in women with bleeding in early pregnancy. N Eng J Med. 2019; 380 (19): 1815-24.

12. Yan Y. et al. Efficacy of progesterone on threatened miscarriage: an updated meta-analysis of randomized trials. Arch Gynecol Obstet. 2021. Vol. 303, N 1. Р. 27-36.

13. Chan D.M., Cheung K.W., Yung S.S., Lee V.C.Y., Li R., Ng E.H. A randomized double-blind controlled trial of the use of dydrogesterone in women with threatened miscarriage in the first trimester: study protocol for a randomized controlled trial. Trials. 2016; 17 (1): 408.

14. Coomarasamy A., Devall A.J., Brosens J.J., et al. Micronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence. Am J Obstet Gynecol. 2020; 223: 167-76.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)